These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26422782)

  • 1. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
    Schutz FA; Je Y; Choueiri TK
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Bachelot T
    Breast Cancer; 2018 Jan; 25(1):17-27. PubMed ID: 29147869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
    Abdel-Rahman O; ElHalawani H
    Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
    J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.
    Wang K; Qu X; Wang Y; Dong W; Shen H; Zhang T; Ni Y; Liu Q; Du J
    Clin Drug Investig; 2016 Jan; 36(1):27-39. PubMed ID: 26547200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
    Abdel-Rahman O; ElHalawani H; Essam-Eldin S
    Expert Opin Drug Saf; 2016; 15(4):437-48. PubMed ID: 26811188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Future Oncol; 2016 Feb; 12(3):413-25. PubMed ID: 26775673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis.
    Petrelli F; Ardito R; Borgonovo K; Lonati V; Cabiddu M; Ghilardi M; Barni S
    Eur J Cancer; 2018 Nov; 103():7-16. PubMed ID: 30196108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.